Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 3/20 | 0.33 |
| ▸ | CTSS | P25774 | 2/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20402756 | 1.00 | L3MBTL1 (0.37) | L3MBTL1CTSKCTSSCYP11B1CYP11B2 | |
| SCHEMBL20402747 | 0.77 | HRH4 (0.47) | L3MBTL1HRH4 | |
| SCHEMBL24087860 | 0.77 | MIF (0.38) | L3MBTL1CTSKCTSSCYP11B2HTR1A | |
| SCHEMBL21133394 | 0.77 | HRH4 (0.47) | L3MBTL1HRH4 | |
| SCHEMBL24253821 | 0.74 | ALDH1A1 (0.42) | L3MBTL1CYP11B2HTR1ADRD2HTR2A | |
| SCHEMBL22341033 | 0.72 | L3MBTL1 (0.39) | L3MBTL1CTSKCTSSCYP11B2ABL1 | |
| SCHEMBL20402786 | 0.72 | ALDH1A1 (0.53) | CYP11B2HRH4NPC1RAB9A | |
| SCHEMBL18508430 | 0.72 | ALDH1A1 (0.53) | CYP11B2HRH4NPC1RAB9A | |
| SCHEMBL19626478 | 0.71 | L3MBTL1 (0.38) | L3MBTL1CTSKCTSSCYP11B2HTR1A | |
| SCHEMBL10874992 | 0.69 | L3MBTL1 (0.36) | L3MBTL1CYP11B2HRH4ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10329263-B2 | Disubstituted 1, 2, 4-triazine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-25 | — | — | US | disclosed |
| US-20170044115-A1 | NOVEL DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329263-B2 | Disubstituted 1, 2, 4-triazine compound | NR3C2, REN, NR5A1 | L3MBTL1 4841/4885CTSK 3575/4885CTSS 1147/4885 |
| US-20170044115-A1 | NOVEL DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND | NR3C2, REN, CYP21A2 | L3MBTL1 4862/4885CTSK 3231/4885CTSS 839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.